Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 2Sarcoma 1Plasma cell 1Lymphoid 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Gliosarcoma 1Glioma 1Glioblastoma 1

Interventions

pembrolizumab 601Cyclophosphamide 545Magnetic Resonance Spectroscopy 524Radiotherapy 508Specimen Handling 504Nivolumab 411Cisplatin 379Carboplatin 368Biopsy 304Blood Specimen Collection 302Radiosurgery 287Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 262Dexamethasone 262venetoclax 251Bevacizumab 248Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 189Ipilimumab 188Fluorouracil 188durvalumab 184Doxorubicin 178Etoposide 177atezolizumab 169

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × efineptakin alfa × 1 year × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT07200089 2026-04-07

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Washington University School of Medicine

Phase 1 Not yet recruiting
52 enrolled
Plasma cell

Multiple Myeloma

NCT05286060 2026-02-09

GENUINE

Yonsei University

Phase 2 Active not recruiting
56 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Mayo Clinic

Phase 2 Recruiting
54 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03687957 2025-11-25

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

Washington University School of Medicine

Phase 1/2 Active not recruiting
42 enrolled 19 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡